Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 26, 2015

Primary Completion Date

April 8, 2025

Study Completion Date

April 8, 2025

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

Adalimumab

every other week or weekly subcutaneous injection

Trial Locations (16)

32806

Arnold Palmer Hospital /ID# 147295, Orlando

98405

MultiCare Institute Health System /ID# 169005, Tacoma

55413-2195

MNGI Digestive Health, P. A. /ID# 147294, Minneapolis

55905-0001

Mayo Clinic - Rochester /ID# 147304, Rochester

830-0011

Kurume University Hospital /ID# 145710, Kurume-shi

113-8431

Juntendo University Hospital /ID# 147315, Bunkyo-ku

157-8535

National Center for Child Health and Development /ID# 147312, Setagaya-ku

30-663

Uniwersytecki Szpital Dzieciecy w Krakowie /ID# 147279, Krakow

50-369

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego /ID# 147310, Wroclaw

00-189

Centrum Zdrowia MDM /ID# 147280, Warsaw

35-210

Gabinet Lekarski Bartosz Korcz /ID# 147281, Rzeszów

93-338

Instytut Centrum Zdrowia Matki Polki /ID# 169017, Lodz

036 01

Univerzitna nemocnica Martin /ID# 147283, Martin

08035

Hospital Universitario Vall d'Hebron /ID# 147288, Barcelona

E1 2ES

Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 147290, London

NW3 2QG

Duplicate_The Royal Free London NHS Foundation Trust /ID# 147292, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY